GlobalData on MSN1d
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...
Lilly signs licensing deal with Mediar for IPF drug
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
FierceBiotech4d
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
BioSpace4d
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
The Pharma Letter1d
Mediar Therapeutics inks IPF deal with Lilly
US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...
Contract Pharma4d
Mediar, Lilly Enter Global Licensing Agreement for WISP1 Antibody
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.
Al-Monitor1mon
Con influencia en Siria, ¿puede Putin de Rusia mediar en el acuerdo entre Israel y el Líbano?
Al-Monitor is an award-winning media outlet covering the Middle East, valued for its independence, diversity and analysis. It is read widely by US, international and Middle East decision makers at the ...
Al-Monitor6mon
Mientras Assad "da la bienvenida" a la reparación de los lazos con Turquía, ¿pueden Rusia o Irak mediar?
Al-Monitor is an award-winning media outlet covering the Middle East, valued for its independence, diversity and analysis. It is read widely by US, international and Middle East decision makers at the ...